{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T11:27:19Z","timestamp":1772105239216,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.ijantimicag.2019.03.016","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T03:55:06Z","timestamp":1553140506000},"page":"35-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1310-4648","authenticated-orcid":false,"given":"Guan-Jhou","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsin-Yun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sui-Yuan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aristine","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Shan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuan-Yin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Chia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Ching","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Chun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Ching","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2019.03.016_bib0001","series-title":"EACS guidelines version 9.0","year":"2017"},{"key":"10.1016\/j.ijantimicag.2019.03.016_bib0002","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jama.2018.8431","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society\u2013USA Panel","volume":"320","author":"Saag","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2019.03.016_bib0003","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services (DHHS). https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf[accessed 9 May 2019]."},{"key":"10.1016\/j.ijantimicag.2019.03.016_bib0004","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/S0140-6736(13)61164-2","volume":"381","author":"Boyd","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2019.03.016_bib0005","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1056\/NEJMoa1311274","article-title":"Assessment of second-line antiretroviral regimens for HIV therapy in Africa","volume":"371","author":"Paton","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2019.03.016_bib0006","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1016\/S2352-3018(16)30011-X","article-title":"Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study","volume":"3","author":"La Rosa","year":"2016","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijantimicag.2019.03.016_bib0007","doi-asserted-by":"crossref","first-page":"R185","DOI":"10.1530\/EJE-13-0967","article-title":"Metabolic and body composition effects of newer antiretrovirals in HIV-infected patients","volume":"170","author":"Srinivasa","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ijantimicag.2019.03.016_bib0008","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1016\/S2352-3018(18)30043-2","article-title":"Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study","volume":"5","author":"Ryom","year":"2018","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijantimicag.2019.03.016_bib0009","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S0140-6736(09)62041-9","volume":"375","author":"Eron","year":"2010","journal-title":"Lancet"},{"issue":"Suppl 3","key":"10.1016\/j.ijantimicag.2019.03.016_bib0010","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2047-783X-14-S3-5","article-title":"Raltegravir: molecular basis of its mechanism of action","volume":"14","author":"Mouscadet","year":"2009","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.ijantimicag.2019.03.016_bib0011","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1586\/14787210.2014.907525","article-title":"Dolutegravir for the treatment of adult patients with HIV-1 infection","volume":"12","author":"Wu","year":"2014","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2019.03.016_bib0012","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/cid\/ciy505","article-title":"Immediate versus deferred switching from a boosted protease inhibitor-based regimen to a dolutegravir-based regimen in virologically suppressed patients with high cardiovascular risk or age \u226550 years: final 96-week results of NEAT022 study","volume":"68","author":"Gatell","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.03.016_bib0013","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1473-3099(19)30036-2","article-title":"Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial","volume":"19","author":"Aboud","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.03.016_bib0014","unstructured":"Stanford University HIV Drug Resistance Database. https:\/\/hivdb.stanford.edu[accessed 9 May 2019]."},{"key":"10.1016\/j.ijantimicag.2019.03.016_bib0015","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/jac\/dkv284","article-title":"Transmitted drug resistance of HIV-1 strains among individuals attending voluntary counselling and testing in Taiwan","volume":"71","author":"Lai","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.03.016_bib0016","doi-asserted-by":"crossref","first-page":"35779","DOI":"10.1038\/srep35779","article-title":"Prevalence of integrase strand transfer inhibitors (INSTI) resistance mutations in Taiwan","volume":"6","author":"Chang","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2019.03.016_bib0017","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1001\/jama.2012.3954","article-title":"Chronic Kidney Disease Prognosis Consortium. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate","volume":"307","author":"Matsushita","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2019.03.016_bib0018","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1177\/1536867X1501500117","article-title":"Nonparametric pairwise multiple comparisons in independent groups using Dunn's test","volume":"15","author":"Dinno","year":"2015","journal-title":"Stata Journal"},{"key":"10.1016\/j.ijantimicag.2019.03.016_bib0019","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1097\/QAD.0b013e32833a608a","article-title":"Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study","volume":"24","author":"Mart\u00ednez","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2019.03.016_bib0020","series-title":"22nd International AIDS Conference","author":"Perez-Valero","year":"2018"},{"key":"10.1016\/j.ijantimicag.2019.03.016_bib0021","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/S2352-3018(17)30065-6","article-title":"Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial","volume":"4","author":"Paton","year":"2017","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijantimicag.2019.03.016_bib0022","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/01.aids.0000218542.08845.b2","article-title":"Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study)","volume":"20","author":"Castagna","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2019.03.016_bib0023","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1016\/S2352-3018(17)30069-3","volume":"4","author":"Ciaffi","year":"2017","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijantimicag.2019.03.016_bib0024","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1097\/01.aids.0000131355.44834.e4","article-title":"Phenotypic impact of HIV reverse transcriptase M184I\/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance","volume":"18","author":"Ross","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2019.03.016_bib0025","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11633630-000000000-00000","article-title":"HIV-1 antiretroviral resistance: scientific principles and clinical applications","volume":"72","author":"Tang","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2019.03.016_bib0026","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1080\/14656566.2019.1570131","article-title":"Choosing appropriate pharmacotherapy for drug-resistant HIV","volume":"20","author":"Capetti","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ijantimicag.2019.03.016_bib0027","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jmii.2015.12.012","volume":"50","author":"Tsai","year":"2017","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2019.03.016_bib0028","first-page":"199","article-title":"Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management","volume":"16","author":"Guti\u00e9rrez","year":"2014","journal-title":"AIDS Rev"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485791930069X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485791930069X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T06:37:05Z","timestamp":1565159825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092485791930069X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S092485791930069X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.03.016","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}